Stevens County Food Assessment

This report is the culmination of a year-long community food assessment conducted by staff, students, and faculty at the University of Minnesota Morris, and informed by an advisory council made up of key local stakeholders. The main goal of the community food assessment is to describe food security in Stevens County at both community and individual scales. This assessment examines what food is grown in the county, what food is available, where food can be obtained in various forms, accessibility and affordability of food, as well as county residents’ experiences with and thoughts and suggestions about food. Findings summarized below rely on several different types of data, including a household food security survey, a survey of prices and availability at area grocery stores, personal communications and observations, and secondary data (e.g., from the US Census Bureau). More details about data collection and the key findings presented below are available in the full version of this report. Based on the (available and newly collected) data for this community food assessment, it is clear that Stevens County does not fit the definition of community food security because many residents are food insecure, food insecure residents tend to share characteristics of marginalized populations, and little of the food consumed in Stevens County is produced and processed in Stevens County. Challenges with community food security are of course not necessarily uniquely to Stevens County, MN as they are at least in part a product of the way our regional, national, and global food supply chains presently function.https://digitalcommons.morris.umn.edu/cst/1083/thumbnail.jp

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)